Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) P/E ratio
Gilead Sciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 979× (November 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 17.9× | (92.63%) |
| FY2024 | 243× | 1,228.70% |
| FY2023 | 18.3× | (21.37%) |
| FY2022 | 23.3× | 58.62% |
| FY2021 | 14.7× | (97.48%) |
| FY2020 | 583× | 3,701.51% |
| FY2019 | 15.3× | 2.90% |
| FY2018 | 14.9× | (28.85%) |
| FY2017 | 20.9× | 184.52% |
| FY2016 | 7.4× | (10.14%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 18.8× | 4.83% |
| Dec 2025 | 17.9× | 5.25% |
| Sep 2025 | 17.0× | (22.30%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. | n/m |
| NVO Novo Nordisk A/S compare | 9.5× |
| BMY Bristol Myers Squibb Company compare | 13.2× |
| GSK GSK PLC Sponsored ADR compare | 15.4× |
| NVS Novartis AG compare | 22.6× |
| AZN AstraZeneca PLC compare | 24.5× |
| AMGN Amgen Inc. compare | 26.7× |
| PFE Pfizer Inc. compare | 38.9× |
| MRK Merck & Co., Inc. compare | 117× |
| Drug Manufacturers General industry median | 24.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement